The increasing utilization of antibiotics, which leads to the loss of beneficial bacteria that keep the vaginal ecosystem balanced, is primarily driving the vulvovaginal candidiasis market.
2. ABOUT IMARC
2
International Market Analysis Research and Consulting Group is a
leading adviser on management strategy and market research
worldwide. We partner with clients in all regions and industry
verticals to identify their highest-value opportunities, address their
most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific,
economic and technological developments for business leaders in
pharmaceutical, industrial, and high technology organizations.
Market forecasts and industry analysis for biotechnology, advanced
materials, chemicals, food and beverage, travel and tourism,
nanotechnology and novel processing methods are at the top of
the company’s expertise.
IMARC’s tailored approach combines unfathomable insight into
the dynamics of companies and markets with close cooperation at
all levels of the client organization. This ensures that our clients
achieve unmatchable competitive advantage, build more proficient
organizations, and secure lasting results.
3. Report Description and Highlights
Vulvovaginal Candidiasis Market 2023-2033
IMARC Group has recently released a report titled “Vulvovaginal Candidiasis Market: Analysis of Epidemiology, Industry Trends, Size, Share, and
Future Forecast (2023-2033)” that presents a comprehensive assessment of the vulvovaginal candidiasis market. The report provides an
extensive overview of the latest market trends, growth prospects, investment opportunities, and industry outlook, as well as an in-depth
analysis of the disease landscape, market size, and growth trends. Furthermore, the report offers an analysis of competitors, regional markets,
and recent advancements in the global market. It also sheds light on crucial segments and market drivers, along with challenges faced by
industry players. This report is a valuable resource for stakeholders who want to gain valuable insights into the vulvovaginal candidiasis market.
Vulvovaginal candidiasis, also known as vaginal yeast infection, is a fungal infection that occurs due to an infestation of the fungus Candida in
the vulva and vagina. The most common indications associated with the disease include itching, a burning sensation while peeing, soreness in
the vaginal area, and thick, white, odorless discharge. An individual suffering from vulvovaginal candidiasis may also experience pain during sex
and general discomfort in the genital region. The diagnosis of this ailment involves a physical examination by a healthcare provider, such as a
pelvic exam and a swab test of the vaginal discharge.
3
4. Report Description and Highlights
Vulvovaginal Candidiasis Market Trend:
The increasing utilization of antibiotics, which leads to the loss of beneficial bacteria that keep the vaginal ecosystem balanced, is primarily
driving the vulvovaginal candidiasis market. Additionally, the growing prevalence of various associated risk factors, such as hormonal
changes, weakened immune systems, poor personal hygiene, sexual relations with multiple partners, etc., is further catalyzing the market
growth. Besides this, the rising utilization of over-the-counter antifungal creams containing active ingredients, including miconazole,
clotrimazole, tioconazole, etc., to treat mild to moderate symptoms of the condition is acting as another significant growth-inducing factor.
Furthermore, the escalating adoption of probiotics as supplements to restore the natural balance of bacteria in the vaginal region is
creating a positive outlook for the market. Additionally, the ongoing advancements in molecular diagnostic methods that can identify
Candida species with high sensitivity and specificity are also contributing to the market growth. Apart from this, the emerging popularity of
non-pharmacological therapies, such as stress-reduction techniques and dietary changes like minimizing sugar intake to manage disease
symptoms, is anticipated to propel the vulvovaginal candidiasis market in the coming years.
Request a Sample Report: https://www.imarcgroup.com/vulvovaginal-candidiasis-market/requestsample
4
5. Report Description and Highlights
What is included in the report segmentation?
The report covers the following aspects:
Report Period:
• Base Year: 2022
• Historical Period: 2017-2022
• Market Forecast: 2023-2033
Countries Included:
• United States
• Germany
• France
5
6. Report Description and Highlights
• United Kingdom
• Italy
• Spain
• Japan
Analysis Covered Across Each Country
• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the Vulvovaginal Candidiasis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the Vulvovaginal Candidiasis market
• Reimbursement scenario in the market
• In-market and pipeline drugs
6
7. Report Description and Highlights
In-Market Drugs
• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Regulatory Status
View Report TOC, Figures and Tables: https://www.imarcgroup.com/vulvovaginal-candidiasis-market
7
8. Key Questions Answered in the Report
1. How has the Vulvovaginal Candidiasis Market performed so far and how will it perform in the coming years?
2. What are the markets shares of various therapeutic segments in 2022 and how are they expected to perform till 2033?
3. What was the country-wise size of the Vulvovaginal Candidiasis Market across the seven major markets in 2022 and what will it look
like in 2033?
4. What is the growth rate of the Vulvovaginal Candidiasis Market across the seven major markets and what will be the expected growth
over the next ten years?
5. What are the key unmet needs in the market?
8
10. Table of Contents
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
10
11. Table of Contents
4 Vulvovaginal Candidiasis - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2017-2022) and Forecast (2023-2033)
4.4 Market Overview (2017-2022) and Forecast (2023-2033)
4.5 Competitive Intelligence
5 Vulvovaginal Candidiasis - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
Click here to visit the complete table of content with list of figures and tables: https://www.imarcgroup.com/vulvovaginal-candidiasis-
market/toc
11
